iTeos Therapeutics Ownership | Who Owns iTeos Therapeutics?
iTeos Therapeutics Ownership Summary
iTeos Therapeutics is owned by 86.65% institutional investors, 0.98% insiders, and 12.36% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.50% of ITOS shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.24% of its assets in iTeos Therapeutics shares.
ITOS Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | iTeos Therapeutics | 86.65% | 0.98% | 12.36% |
| Sector | Healthcare Stocks | 488.17% | 11.08% | -399.26% |
| Industry | Biotech Stocks | 306.59% | 11.10% | -217.69% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock funding, inc. /de | 4.57M | 10.50% | $45.61M |
| Blackrock | 3.73M | 10.41% | $55.37M |
| Tang capital management | 3.83M | 8.78% | $38.15M |
| Boxer capital | 2.95M | 8.22% | $43.73M |
| Mpm asset management | 2.74M | 6.35% | $21.03M |
| Jpmorgan chase | 2.07M | 4.80% | $15.89M |
| Vanguard group | 1.63M | 3.79% | $12.55M |
| Morgan stanley | 1.09M | 3.04% | $16.17M |
| Dimensional fund advisors lp | 1.21M | 2.81% | $9.29M |
| Citigroup | 853.78K | 1.98% | $6.56M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Mpm asset management | 2.74M | 16.91% | $21.03M |
| Stonepine capital management | 310.03K | 3.03% | $3.09M |
| Boxer capital | 2.95M | 2.30% | $43.73M |
| Tang capital management | 3.83M | 1.93% | $38.15M |
| Almitas capital | 487.20K | 1.23% | $4.86M |
| Newtyn management | 567.42K | 0.86% | $5.66M |
| Sandia investment management lp | 24.86K | 0.64% | $247.90K |
| Alpine global management | 225.00K | 0.51% | $2.24M |
| Dafna capital management | 140.85K | 0.39% | $1.40M |
| Dld asset management, lp | 576.65K | 0.32% | $5.75M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Jpmorgan chase | 2.07M | 0.00% | 1.60M |
| Boxer capital | 2.95M | 2.30% | 1.14M |
| Tang capital management | 3.83M | 1.93% | 1.14M |
| Citigroup | 853.78K | 0.00% | 833.59K |
| Orbimed advisors | 700.00K | 0.17% | 700.00K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Ra capital management | - | - | -3.65M |
| Bvf inc/il | - | - | -3.08M |
| 683 capital management | - | - | -1.75M |
| Bioimpact capital | - | - | -1.75M |
| Ecor1 capital | - | - | -1.61M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Orbimed advisors | 700.00K | 0.17% | 700.00K | $6.98M |
| Nantahala capital management | 596.67K | 0.23% | 596.67K | $5.95M |
| Dld asset management, lp | 576.65K | 0.32% | 576.65K | $5.75M |
| Newtyn management | 567.42K | 0.86% | 567.42K | $5.66M |
| Alyeska investment group | 500.00K | 0.02% | 500.00K | $4.99M |
Sold Out
| Holder | Change |
|---|---|
| Point72 asia (singapore) pte. | -1.00 |
| Nelson, van denburg & campbell wealth management group | -5.00 |
| Signaturefd | -8.00 |
| Parallel advisors | -11.00 |
| Rothschild investment | -25.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | 139 | 6.11% | 37,750,487 | 11.22% | 86 | 1.41% | 92 | 50.82% | 31 | -29.55% |
| Mar 31, 2025 | 133 | -6.99% | 36,961,110 | 8.28% | 85 | 1.36% | 61 | -19.74% | 44 | -4.35% |
| Dec 31, 2024 | 141 | -9.62% | 34,049,312 | -6.92% | 78 | 1.10% | 74 | -11.90% | 46 | 9.52% |
| Sep 30, 2024 | 155 | 11.51% | 36,568,914 | 1.19% | 84 | 0.83% | 83 | 12.16% | 42 | 5.00% |
| Jun 30, 2024 | 138 | 1.47% | 36,138,016 | 4.70% | 100 | 1.09% | 73 | 37.74% | 40 | -25.93% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard US Total Market Shares ETF | 855.64K | 2.24% | -413.20K |
| Vanguard Total Stock Mkt Idx Inv | 753.97K | 1.71% | -16.62K |
| iShares Russell 2000 ETF | 700.29K | 1.59% | -13.34K |
| SPDR® S&P Biotech ETF | 544.15K | 1.49% | 7.73K |
| Candriam Eqs L Biotech C USD Cap | 535.59K | 1.47% | - |
| BlackRock Advantage Small Cap Core Instl | 591.43K | 1.34% | -1.75K |
| JPMorgan Small Cap Value I | 370.99K | 0.84% | -3.12K |
| CREF Stock R1 | 299.33K | 0.78% | -27.07K |
| Vanguard Institutional Extnd Mkt Idx Tr | 301.38K | 0.68% | -129.10K |
| Candriam Global Equities Oncology | 233.62K | 0.64% | 148.62K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jun 10, 2025 | Detheux Michel | Chief Executive Officer | Sell | $439.71K |
| Jun 09, 2025 | Detheux Michel | Chief Executive Officer | Sell | $440.14K |
| Jun 10, 2025 | Detheux Michel | Chief Executive Officer | Sell | $84.17K |
| Jun 09, 2025 | Detheux Michel | Chief Executive Officer | Sell | $84.25K |
| Jun 05, 2025 | Detheux Michel | Chief Executive Officer | Sell | $85.26K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | - | - |
| 2025 Q2 | 2 | 16 |
| 2025 Q1 | - | - |
| 2024 Q4 | 1 | - |
| 2024 Q3 | - | - |
ITOS Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools